🚀 VC round data is live in beta, check it out!
Jiangxi Fushine Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jiangxi Fushine Pharma and similar public comparables like Precigen, China TCM, Cohance Lifesciences, Taysha GTx and more.
Jiangxi Fushine Pharma Overview
About Jiangxi Fushine Pharma
Jiangxi Fushine Pharmaceutical Co Ltd is engaged in research and development, manufactures and sells APIs and pharmaceutical intermediates. It offers penicillin, carbapenem, and other products.
Founded
2002
HQ
Employees
N/A
Website
Financials (LTM)
EV
$1B
Jiangxi Fushine Pharma Financials
Jiangxi Fushine Pharma reported last 12-month revenue of $176M and EBITDA of $25M.
In the same LTM period, Jiangxi Fushine Pharma generated $34M in gross profit, $25M in EBITDA, and had net loss of ($2M).
Revenue (LTM)
Jiangxi Fushine Pharma P&L
In the most recent fiscal year, Jiangxi Fushine Pharma reported revenue of $171M and EBITDA of ($11M).
Jiangxi Fushine Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $176M | XXX | $171M | XXX | XXX | XXX |
| Gross Profit | $34M | XXX | $17M | XXX | XXX | XXX |
| Gross Margin | 19% | XXX | 10% | XXX | XXX | XXX |
| EBITDA | $25M | XXX | ($11M) | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | (7%) | XXX | XXX | XXX |
| EBIT Margin | (5%) | XXX | (8%) | XXX | XXX | XXX |
| Net Profit | ($2M) | XXX | ($39M) | XXX | XXX | XXX |
| Net Margin | (1%) | XXX | (23%) | XXX | XXX | XXX |
| Net Debt | — | — | $87M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jiangxi Fushine Pharma Stock Performance
Jiangxi Fushine Pharma has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Jiangxi Fushine Pharma's stock price is $2.37.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJiangxi Fushine Pharma Valuation Multiples
Jiangxi Fushine Pharma trades at 8.2x EV/Revenue multiple, and 56.9x EV/EBITDA.
EV / Revenue (LTM)
Jiangxi Fushine Pharma Financial Valuation Multiples
As of March 7, 2026, Jiangxi Fushine Pharma has market cap of $1B and EV of $1B.
Equity research analysts estimate Jiangxi Fushine Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangxi Fushine Pharma has a P/E ratio of (596.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBITDA | 56.9x | XXX | (128.9x) | XXX | XXX | XXX |
| EV/EBIT | (164.6x) | XXX | (111.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 42.0x | XXX | 87.1x | XXX | XXX | XXX |
| P/E | (596.5x) | XXX | (32.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 215.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jiangxi Fushine Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jiangxi Fushine Pharma Margins & Growth Rates
Jiangxi Fushine Pharma's revenue in the last 12 month grew by 25%.
Jiangxi Fushine Pharma's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangxi Fushine Pharma's rule of X is 77% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Jiangxi Fushine Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | (7%) | XXX | XXX | XXX |
| EBITDA Growth | 156% | XXX | (252%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 77% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jiangxi Fushine Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Precigen | XXX | XXX | XXX | XXX | XXX | XXX |
| China TCM | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Taysha GTx | XXX | XXX | XXX | XXX | XXX | XXX |
| GuangYuYuan Chinese | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangxi Fushine Pharma M&A Activity
Jiangxi Fushine Pharma acquired XXX companies to date.
Last acquisition by Jiangxi Fushine Pharma was on XXXXXXXX, XXXXX. Jiangxi Fushine Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jiangxi Fushine Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJiangxi Fushine Pharma Investment Activity
Jiangxi Fushine Pharma invested in XXX companies to date.
Jiangxi Fushine Pharma made its latest investment on XXXXXXXX, XXXXX. Jiangxi Fushine Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jiangxi Fushine Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jiangxi Fushine Pharma
| When was Jiangxi Fushine Pharma founded? | Jiangxi Fushine Pharma was founded in 2002. |
| Where is Jiangxi Fushine Pharma headquartered? | Jiangxi Fushine Pharma is headquartered in China. |
| Is Jiangxi Fushine Pharma publicly listed? | Yes, Jiangxi Fushine Pharma is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma trades under 300497 ticker. |
| When did Jiangxi Fushine Pharma go public? | Jiangxi Fushine Pharma went public in 2015. |
| Who are competitors of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma main competitors are Precigen, China TCM, Cohance Lifesciences, Taysha GTx. |
| What is the current market cap of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma's current market cap is $1B. |
| What is the current revenue of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma's last 12 months revenue is $176M. |
| What is the current revenue growth of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Jiangxi Fushine Pharma? | Current revenue multiple of Jiangxi Fushine Pharma is 8.2x. |
| Is Jiangxi Fushine Pharma profitable? | Yes, Jiangxi Fushine Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma's last 12 months EBITDA is $25M. |
| What is Jiangxi Fushine Pharma's EBITDA margin? | Jiangxi Fushine Pharma's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Jiangxi Fushine Pharma? | Current EBITDA multiple of Jiangxi Fushine Pharma is 56.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.